Evidence map›Paper›PMID 36388105›Full record

ArticleFrontiers in physiology2022

RANKL confers protection against cell death in precision-cut lung slices.

M J R Ruigrok, M A P Roest, H W Frijlink, P Olinga, W L J Hinrichs, B N Melgert

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in physiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

M J R RuigrokDepartment of Pharmaceutical Technology and Biopharmacy, University of Groningen, Groningen, Netherlands.
M A P RoestDepartment of Pharmaceutical Technology and Biopharmacy, University of Groningen, Groningen, Netherlands.
H W FrijlinkDepartment of Pharmaceutical Technology and Biopharmacy, University of Groningen, Groningen, Netherlands.
P OlingaDepartment of Pharmaceutical Technology and Biopharmacy, University of Groningen, Groningen, Netherlands.
W L J HinrichsDepartment of Pharmaceutical Technology and Biopharmacy, University of Groningen, Groningen, Netherlands.
B N MelgertDepartment of Molecular Pharmacology, University of Groningen, Groningen, Netherlands.
University of Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death globally and constitutes a major health problem. The disease is characterized by airflow obstructions due to chronic bronchitis and/or emphysema. Emerging evidence suggests that COPD is the result of impaired epithelial repair. Motivated by the need for more effective treatments, we studied whether receptor activator of nuclear factor κ-Β ligand (RANKL) contributed to epithelial repair, as this protein has been implicated in epithelial regeneration of breast and thymus. To do so, we used precision-cut lung slices prepared from mouse tissue-viable explants that can be cultured

Indexed as

chronic bronchitisemphysemaexplant cultureOPGLtissue regenerationTRANCE

Identifiers

PMID36388105
PMCPMC9659591
OpenAlexW4307869863

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.